


Discovering the action mechanism of the most widely used type 2 diabetes drug

June 22 2023



Trends in Pharmacological Sciences

Key figure. Schematic showing the AMP-activated protein kinase (AMPK)-dependent hepatic effects of metformin on glucose metabolism. Metformin modulates hepatic glucose metabolism through AMPK-dependent mechanisms. It activates AMPK by increasing the formation of the trimeric complex of this kinase in hepatocytes, thereby promoting the phosphorylation of its α subunit at Thr172 by the upstream kinase liver kinase B1 (LKB1). This is

initiated by the binding of metformin to PEN2 in the lysosomal membrane and the subsequent formation of a complex with ATP6AP1, a subunit of the v-ATPase, which leads to inhibition of v-ATPase and activation of AMPK. Once AMPK is activated by metformin, this kinase phosphorylates cAMP-response element element-binding protein (CREB)-binding protein (CBP) and CREB-regulated transcription coactivator 2 (CRTC2), and interferes with their binding to CREB. Metformin also increases the levels of the transcriptional repressor small heterodimer partner (SHP). All these changes reduce the gluconeogenic program, ultimately leading to a reduction in hepatic glucose production. Moreover, metformin phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing lipogenesis, and, via direct or indirect mechanisms, helps to ameliorate insulin sensitivity. Therapeutic concentrations of metformin increase complex I activity by stimulating mitochondrial fission via AMPK, thereby contributing to reduce insulin resistance (not shown). Credit: *Trends in Pharmacological Sciences* (2023). DOI: 10.1016/j.tips.2023.04.004

There are still many enigmas about the mechanism of action of metformin, the most prescribed drug to treat diabetes mellitus, also known as type 2 diabetes. Now, a review article published in the journal *Trends in Pharmacological Sciences* highlights how metformin is able to interact with the liver and gut to reduce circulating glucose levels.

The study is led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona, the Institute of Biomedicine of the UB (IBUB) and the Sant Joan de Déu Research Institute (IRSJD), and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM).

Metformin: How to reduce glucose production?

Type 2 diabetes is a [metabolic disease](#) in which there is an excessive amount of glucose in the blood, due to the body's inability to respond

adequately to the actions of insulin—a process known as insulin resistance—or to produce this hormone. To fight this disease, professionals usually use metformin, an orally administered drug that reduces the contribution of glucose in the blood (hypoglycemic) and improves its peripheral circulation.

"Historically, it has been thought that the main place of action of metformin is the [liver](#), but the most recent findings confirm that it also has notable effects on the gut," says Professor Manuel Vázquez-Carrera, head of the Pharmacological Targets in Inflammation and Metabolic Diseases Research Group of the UB. "That is why most of the most advanced studies focus on the two organs where metformin's actions appear to be most important: the liver and the gut."

The paper highlights how a team has recently described that, in the liver, metformin is able to increase the levels of miRNA let-7, a signaling molecule in several physiological functions. This pathway reduces hepatic glucose production, which is the process that contributes most to the glucose increase in patients with type 2 diabetes.

"These results open up the possibility of activating the expression of the miRNA let-7, which is reduced in diabetic states, as a new strategy for the treatment of [diabetes mellitus](#)," says Vázquez-Carrera.

In parallel, the effects of metformin on the intestine have also been described. In one of the most recent studies, another team has shown that metformin activates the conversion of glucose to lactate and acetate in the intestine. "These two metabolites reach the liver via the [portal vein](#) and trigger processes that reduce hepatic [glucose](#) production. Thus, metformin establishes a crosstalk between the intestine and the liver that contributes to its antidiabetic effects," the researcher notes.

It should be recalled that the team led by Manuel Vázquez-Carrera also

determined that metformin requires the presence of growth differentiation factor 15 (GDF15) to activate its main pharmacological target (AMPK) and have antidiabetic effects.

"In short, all of the new studies reviewed in this new article help resolve outstanding enigmas and provide data to understand how [metformin](#) reduces hepatic [glucose production](#), which is the main antidiabetic effect of this drug."

More information: Emma Barroso et al, Striking a gut–liver balance for the antidiabetic effects of metformin, *Trends in Pharmacological Sciences* (2023). [DOI: 10.1016/j.tips.2023.04.004](https://doi.org/10.1016/j.tips.2023.04.004)

Provided by University of Barcelona

Citation: Discovering the action mechanism of the most widely used type 2 diabetes drug (2023, June 22) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-06-action-mechanism-widely-diabetes-drug.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.